<DOC>
	<DOCNO>NCT02295150</DOCNO>
	<brief_summary>This study prospective evaluation relationship lean body weight anti-Xa activity 5700 International Units ( IU ) nadroparin 4 hour subcutaneous administration morbidly obese patient bariatric surgery .</brief_summary>
	<brief_title>Prophylaxis Venous Thromboembolism After Bariatric Surgery</brief_title>
	<detailed_description>There guideline postoperative thromboembolic prevention morbidly obese patient . The investigator goal examine dose nadroparin effective .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>Approval RouxenY gastric bypass Total body weight &gt; 140 kg Renal impairment ( GFR &lt; 30ml/min and/ serum creatinin &gt; 150 micromol/ml ) Coagulation disorder Use vitamin K antagonist ( acenocoumarol ) pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Nadroparin</keyword>
	<keyword>Anti-Xa activity</keyword>
</DOC>